As filed with the Securities and Exchange Commission on February 12, 2026. Registration No. 333- (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOVENTRIX, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 20-0372415 (Primary Standard Industrial Classification Code Number) If this Form is a post-e ...

Financial Data and Key Metrics Changes - In Q4 2025, research and development expenses decreased to $6.2 million from $7 million in Q4 2024, reflecting the completion of the SHIELD II Phase 3 trial [15] - General and administrative expenses increased to $1.8 million in Q4 2025 from $1 million in Q4 2024, primarily due to non-cash expenses related to performance-based options [16] - The net loss for Q4 2025 was $8.5 million or $0.41 per share, unchanged from the previous year but improved on a per-share basis from $1.13 in Q4 2024 [16] - For the full year 2025, net loss was $34.2 million or $2.09 per share, compared to a net loss of $29 million or $4.91 per share in 2024 [17] - As of December 31, 2025, the company had $12.9 million in cash and equivalents, with additional gross proceeds of $3.7 million generated from warrant exercises post-quarter [18] Business Line Data and Key Metrics Changes - The company successfully completed the SHIELD II Phase 3 trial for D-PLEX100, achieving its primary and key secondary endpoints [5] - The focus remains on advancing the regulatory pathway for D-PLEX100 and commercial partnership discussions in the U.S. [5][7] Market Data and Key Metrics Changes - The company is engaging with potential U.S. commercial partners that have strong hospital-based commercialization experience [11] - Discussions with partners have progressed to advanced stages, reflecting the strong clinical profile of D-PLEX100 [7] Company Strategy and Development Direction - The company is transitioning from a primarily R&D-focused organization to one preparing for commercialization, with a renewed corporate brand to reflect this change [11][12] - The introduction of Kynatrix technology aims to expand capabilities beyond localized delivery, targeting metabolic diseases with a long-acting GLP-1 receptor agonist program [14] Management's Comments on Operating Environment and Future Outlook - Management believes 2026 could be transformative, with the rolling NDA submission expected to begin by the end of Q1 2026 [9] - Positive feedback from the FDA supports the regulatory pathway for D-PLEX100, with expectations for a rolling NDA submission [6][9] Other Important Information - The company appointed Ms. Brooke Story as chairman of the board in December 2025, bringing extensive experience in medical technology [9] Q&A Session Summary Question: Can you share how discussions around the scope of the label progressed? - The company is targeting an initial label for the prevention of surgical site infections in abdominal colorectal surgery, supported by Phase 3 data [22] Question: Any thoughts on plans for broader label expansion? - There may be opportunities for label expansion into broader abdominal surgical applications as the review process progresses [24] Question: What work is being done to prepare for potential approval of D-PLEX100? - The company is focusing on building awareness, market research, and creating a KOL network to prepare for commercialization [32] Question: How do you view the strategic timing for the GLP-1 program? - The company plans to partner at an early stage, leveraging robust preclinical data to attract interest [35] Question: What factors will play a role in identifying the final partner? - The ideal partner will have broad hospital-based capabilities and presence in the surgical suite [41] Question: What percentage of potential target IDNs would likely include D-PLEX on formulary within the first 12 months after approval? - The uptake will take time, with a few months before seeing meaningful updates, but once on formulary, usage is expected to grow steadily [50]

Core Viewpoint - Paramount Skydance Corp. is actively seeking to complete the Justice Department's antitrust review of its tender offer for Warner Bros. Discovery Inc. shares in the coming weeks, as it aims to counter Netflix's planned acquisition of Warner Bros. studios and streaming businesses [1][3]. Group 1: Regulatory Review and Approval - Paramount is providing requested information to the Justice Department, which will require a 10-day waiting period to determine if it will challenge Paramount's proposal due to competition concerns [2]. - The Justice Department is thoroughly examining the offers from both Netflix and Paramount, with federal officials reaching out to major Hollywood constituencies for information [6]. - A Justice Department approval does not guarantee that Paramount is clear of regulatory hurdles, as any changes to key terms of the proposal may require resubmission for review [7]. Group 2: Competitive Landscape - Warner Bros. agreed to sell its studios and streaming divisions to Netflix for $82.7 billion, favoring this deal over Paramount's competing bid [4]. - Paramount has resisted increasing its $108 billion bid for Warner Bros., asserting that its offer is superior and more likely to gain regulatory approval [8]. - Warner Bros. and Netflix express confidence in securing approval for their deal, while also acknowledging that the Justice Department's review is expected to extend into later this year [9]. Group 3: Strategic Implications - Securing early regulatory approval is crucial for Paramount to persuade Warner Bros. shareholders to vote against the Netflix deal [3]. - Paramount's strategy includes appealing directly to shareholders and lobbying regulators to bypass the Netflix deal [4]. - A spokesperson for Netflix indicated that the company expects Paramount to declare compliance with federal regulations, emphasizing the value of the Netflix and Warner Bros. partnership [5].

As filed with the U.S. Securities and Exchange Commission on February 6, 2026 Registration No. 333-292260 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear Parkw ...

Core Insights - The cultivated meat industry is experiencing a significant downturn, with many companies facing closures and challenges in securing funding, leading to a consolidation phase [2][4][7] - Despite the current struggles, there remains long-term potential for cultivated meat, but expectations need recalibration regarding timelines and investment requirements [5][9][30] - Regulatory hurdles continue to impede the commercialization of cultivated meat, with approvals being slow and costly, affecting the industry's ability to scale and generate revenue [10][12][14] Group 1: Industry Challenges - The cultivated meat sector has seen substantial investment, estimated at £2.6 billion ($3.1 billion) since 2016, but many companies have not yet commercialized their products due to regulatory issues [3][6] - Recent business failures, including Meatable and Believer Meats, highlight the difficulties faced by the industry, which is now waking up to the reality of over-enthusiasm during the pandemic [7][8] - The perception that cultivated meat is failing is likely to be reinforced by ongoing consolidation, making it harder for remaining companies to achieve profitability [4][5][9] Group 2: Regulatory Environment - The U.S. has begun approving cultivated meat products for commercialization, but these approvals are product-specific and primarily for restaurant sampling, with some states imposing barriers [10][11] - European countries are also erecting regulatory barriers, although some approvals have been granted in Israel, Australia, and Singapore, indicating a mixed landscape for regulatory progress [11][15] - The lengthy and expensive regulatory approval process is a significant challenge for manufacturers, often requiring new applications as development progresses [12][14] Group 3: Future Outlook - Companies that adapt to the new realities of the market, focusing on unit economics and capital efficiency, are likely to emerge as leaders in the cultivated meat sector [24][26] - Partnerships and resource sharing may be essential for survival, as independent scaling efforts face significant challenges due to funding constraints and regulatory barriers [20][23] - The cultivated meat industry is still in its infancy, with over 50 companies in Europe and at least 150 globally, but achieving competitive pricing with field-reared meat remains critical for widespread consumer adoption [16][28][30]

As filed with the Securities and Exchange Commission on January 23, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OPTION THERAPEUTICS INC. (Exact name of registrant as specified in its charter) | | | (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 680 W Nye Lane, Suite 201 Carson ...

Core Insights - The expectation of regulation is fundamental for institutional finance, as projects unable to navigate regulatory environments will struggle to attract significant capital [1] - XRP has received regulatory approval to operate in a key financial zone, contrasting with privacy coins like Zcash and Monero, which face regulatory challenges [2] Regulatory Access - XRP and its underlying technology, the XRP Ledger (XRPL), are being developed by Ripple to facilitate international payments and transactions, with a focus on gaining regulatory approval to enhance investment opportunities [4] - Dubai, particularly the Dubai International Financial Center (DIFC), has recognized XRP as an approved crypto token for licensed businesses, marking a significant regulatory milestone [5] - The approval of RLUSD, a stablecoin on the XRPL, as one of three stablecoins permitted in the DIFC, positions XRP to attract substantial capital, potentially driving up its price [6]

RT Wu Blockchain (@WuBlockchain)The Block reported that India’s competition watchdog has approved Coinbase Global’s acquisition of a minority stake in DCX Global Limited, the parent company of Indian crypto exchange CoinDCX, though the exact ownership percentage was not disclosed. Coinbase Chief Legal Officer Paul Grewal confirmed the regulatory approval on X but did not provide deal details. https://t.co/Xg1ShQrfgQ ...

Core Insights - Coinbase has launched a new service allowing clients to create custom-branded stablecoins, directly competing with Paxos in the white-label stablecoin market [1][5][7] Group 1: Coinbase's New Offering - The new stablecoin solution is not initially targeted at enterprise-level clients, focusing instead on smaller fintech companies like Flipcash, Solflare, and R2 [5] - Coinbase's historical partnership with Circle for USDC positions it well in the stablecoin distribution market [6] Group 2: Competitive Landscape - Paxos previously partnered with Binance to create BUSD, which became a significant player in the stablecoin market before being phased out [3] - Paxos has since secured a partnership with PayPal, leveraging its trust charter to enhance credibility [3][4] Group 3: Regulatory Environment - The passage of the GENIUS Act has shifted stablecoin oversight from New York to federal authorities, potentially benefiting Coinbase due to its established regulatory framework and presence in Washington [8]

🔥 JUST IN: BitGo has received regulatory approval to operate a banking business. https://t.co/W5RQCfAzT5 ...